Boltz

Emerging

Open-source AI for biomolecular structure prediction. $28M seed from a16z. Pfizer collaboration. Boltz-2 rivals physics methods at 1000x speed. MIT spinout.

AI Biomolecular Prediction
Visit Website
Updated April 2026

Company Overview

Boltz builds open-source AI models for biomolecular structure and binding affinity prediction. MIT CSAIL spinout. $28M seed (Amplify, a16z, Zetta) + Pfizer collaboration. Boltz-1 matched AlphaFold3. Boltz-2 (June 2025, with Recursion): predicts structures AND binding affinities at 1000x speed. MIT-licensed.

Revenue
$28M
Curated content • Fact-checked and verified
Loading News...
Loading Culture...

Open Positions

Reddit Discussions

Loading Competitive Intelligence...

Key Differentiators

Emerging Innovator

Boltz is an emerging player bringing innovative solutions to the Healthcare Tech market.

Frequently Asked Questions

Compare Boltz with Competitors

Side-by-side AI visibility scores, platform breakdown, and market position.

Start Comparison →
For Boltz

Claim This Profile

Are you from Boltz? Claim your profile to see full AI mention excerpts, get weekly visibility change alerts, and optimize how AI systems describe your brand.

Claim Boltz Profile →
For competitors & analysts

Track AI Visibility in Real Time

Monitor how ChatGPT, Gemini, Perplexity, and Claude mention Boltz vs competitors. Get alerts when AI recommendations shift.

Start Free Tracking →